Where American psychedelic research began — and where it is heading
A research-first educational resource for Boston and the Greater Boston metro. Harvard’s legacy. McLean Hospital’s present. Massachusetts legal context.
Project begins
first double-blind study
active research site
local deprioritization
Harvard, Cambridge, and the origins of American academic psychedelic research
No American city has a deeper institutional history with academic psychedelic research than Boston. The foundational studies that shaped modern literature were conducted at Harvard and Boston University — not in California, not at a government facility.
“No American institution contributed more to the early academic literature on psilocybin than Harvard University — in Cambridge, Massachusetts.”
The Greater Boston metro is not simply a city where psychedelic research is being studied. It is where American institutional psychedelic research began. That sixty-year continuum from Harvard’s original project to McLean’s current trials is unique in the American research landscape.
One city. One continuous legacy.
What neuroplasticity is — and why Boston researchers are studying it alongside psychedelic compounds
Neuroplasticity is the brain’s capacity to reorganize itself by forming new neural connections. This capacity continues throughout adult life. It is the foundational concept behind learning, behavioral change, and recovery from certain neurological conditions.
A growing body of peer-reviewed literature — published in journals including Neuron, JAMA Psychiatry, and Pharmacological Reviews — has examined whether and how certain psychedelic compounds interact with neuroplastic mechanisms.
The REBUS model: how researchers explain what psychedelic compounds do in the brain
REBUS — Relaxed Beliefs Under Psychedelics — published by Carhart-Harris and Friston in Pharmacological Reviews (2019).
Your brain on a studied compound: what the published mechanism actually describes
Plain-English documentary explainer — 11 scenes. How psilocybin interacts with the brain at the molecular level, as described in peer-reviewed literature.
SCENE 01
Researchers examining this compound describe a fundamental question in the literature: a quantity too small to produce perceptible effects — what is it actually doing inside the body?
SCENE 02
Published research documents that psilocybin itself is biologically inactive. An enzyme converts it into psilocin — the active form — documented across peer-reviewed pharmacology literature.
SCENE 03
Psilocin binds preferentially to the 5-HT2A serotonin receptor — a molecular interaction documented extensively in published neuroscience research.
SCENE 04
Published research notes that 5-HT2A is the same receptor family targeted by many mood-related pharmaceutical agents, though reached by a different molecular pathway.
SCENE 05
5-HT2A receptors concentrate on the Default Mode Network — the system researchers associate with self-referential thought, rumination, and the internal monologue.
SCENE 06
Academic literature documents that persistent DMN overactivity correlates with anxious and repetitive self-focused cognition. Published research examines how psilocin interacts with this network.
SCENE 07
Published research documents that psilocybin administration is associated with increases in BDNF — Brain-Derived Neurotrophic Factor — a protein that supports formation of new neural connections.
SCENE 08
Neuroplasticity — the brain's capacity to form new connections — is the central theoretical framework in the published psychedelic research literature for understanding reported lasting effects.
SCENE 09
Published research acknowledges the basic receptor mechanism is well established. Broader questions remain the subject of active academic investigation across major research institutions.
SCENE 10
The academic literature characterizes the science as theoretically plausible and the subject of ongoing peer-reviewed investigation at Johns Hopkins, Yale, Harvard, and McLean Hospital.
SCENE 11
This content summarizes published academic research. It is not medical advice. For adults 21 and over.
What the published literature reports
A neutral summary of peer-reviewed findings. All statistics describe outcomes observed in supervised research or clinical trial settings.
Unbroken record 1960 – present
First formal US academic psilocybin research — Cambridge, MA
First double-blind psilocybin study in American academic history
Active Harvard-affiliated clinical research — most active East Coast site
No personal-use guidance.
No commerce.
Psilocybin remains controlled in Massachusetts
Massachusetts has not enacted statewide psilocybin decriminalization. Psilocybin remains Schedule I under federal law and controlled under Massachusetts state law outside approved research settings.
Cambridge and Somerville adopted local enforcement-deprioritization resolutions in 2021. These are local enforcement-priority policies only — they do not override state or federal law and do not create a legal sales framework.
Boston proper has not adopted a local enforcement-deprioritization resolution as of 2026.
Boston’s neighborhoods and the research ecosystem
The research literature and its legal context intersect differently across Greater Boston’s neighborhoods.
The city where it continues.
The academic ecosystem behind the published research
No metro area has a comparable concentration of research institutions contributing to the published psychedelic literature.
The research tradition is part of it.
Want to go deeper into the published research?
Peer-reviewed findings, Massachusetts legal context, and Boston’s unique research legacy — educational only.
Questions about the research and legal status
Massachusetts legal context, Harvard’s research history, and the neuroscience — answered for a Greater Boston audience.
Contact the editorial team
Submit a research citation question, editorial correction, or source suggestion.